Skip to search boxSkip to navigationSkip to main content

Expedited Partner Therapy (EPT) increases the frequency of partner notification among MSM in Lima, Peru: A pilot randomized controlled trial

  • Jesse L. Clark(corresponding author)
    ,
  • ,
  • Catherine E. Oldenburg
    ,
  • Jessica Rios
    ,
  • Silvia M. Montano
    ,
  • Amaya Perez-Brumer
*Corresponding author for this work
  • David Geffen School of Medicine at UCLA
    ,
  • Universidad Peruana de Ciencias Aplicadas
    ,
  • University of California, San Francisco
    ,
  • Asociación Civil Impacta Salud y Educación
    ,
  • U.S. Naval Medical Research Unit SIX
    ,
  • Mailman School of Public Health
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Article number

94

Journal (Volume, Issue Number)

BMC Medicine (Volume 15, Issue 1)

Publication milestones

  • Published - 04/05/2017

Publication status

Published - 04/05/2017

Publication IDs

  • Scopus: 85018985446
  • PubMed: 28468648

Abstract

Background: Expedited Partner Therapy (EPT) has been shown to improve treatment outcomes among heterosexual partners of individuals with curable sexually transmitted infections (STIs). Although the use of EPT with men who have sex with men (MSM) has been debated, due to the potential for missed opportunities to diagnose unidentified cases of HIV and syphilis infection in symptomatic partners, increases in partner notification (PN) resulting from use of EPT may promote testing and treatment of otherwise unidentified partners. We assessed the impact of EPT on self-reported PN among MSM in Peru with gonorrheal (GC) and/or chlamydial (CT) infection. Methods: We enrolled 173 MSM in Lima, Peru with symptomatic or asymptomatic GC and/or CT infection between 2012 and 2014. We enrolled 44 MSM with symptomatic urethritis/proctitis and 129 MSM with asymptomatic GC/CT infection, diagnosed based on nucleic acid testing (Aptima Combo 2 Transcription-Mediated Amplification [TMA]) from urethral, pharyngeal, and rectal sites. Eligible participants were randomly assigned to receive either standard PN counseling (n = 84) or counseling plus EPT (cefixime 400 mg/azithromycin 1 g) for up to five recent partners (n = 89). Self-reported notification was assessed by computer-assisted self-administered survey among 155 participants who returned for 14-day follow-up. Results: The median age of participants was 26 (interquartile range [IQR]: 23-31) with a median of 3 sexual partners (IQR: 2-4) in the previous 30-day period. Among all participants, 111/155 (71.6%) notified at least one partner at 14-day follow-up with a median of 1 partner notified per participant (IQR: 0-2). For participants randomized to receive EPT, 69/83 (83.1%) reported notifying at least one partner, compared with 42/72 (58.3%) of participants in the control arm (odds ratio = 3.52; 95% confidence interval [CI]: 1.68-7.39). The proportion of all recent partners notified was significantly greater in the EPT than in the control arm (53.5%, 95% CI: 45.0-62.0% versus 36.4%, 95% CI: 27.0-47.4%). Conclusions: Provision of EPT led to significant increases in notification among Peruvian MSM diagnosed with GC/CT infection. Additional research is needed to assess the impact of EPT on biological outcomes, including persistent or recurrent infection, antimicrobial resistance, and HIV/STI transmission, in MSM sexual networks. Trial registration: ClinicalTrials.gov, NCT01720654. Registered on 10/29/2012.

Funding Details

Funding was provided by National Institutes of Health (NIH)/National Institute of Mental Health (NIMH) K23 MH 084611, to Principal Investigator (PI) Clark, R21 MH 092322 (PI: Coates), T32 DA 013911 (PI: Flanigan), R25 MH 083620 (PI: Nunn), and R25 MH 087222 (PI: Clark). Support was also provided by R25 TW 009343 (PI: Cohen), funded by the Fogarty International Center, Office of Behavioral and Social Sciences Research, Office of Research on Women’s Health, Office of AIDS Research, National Institute of Mental Health, and National Institute on Drug Abuse, as well as the University of California Global Health Institute.
FundersFunding numbers
University of California Global Health Institute
-
NIH
-
NIMH
R25 TW 009343, K23 MH 084611, T32 DA 013911, R21 MH 092322, R25MH087222, R25 MH 083620
NIDA
-
FIC
-
OBSSR
-
ORWH
-
OAR
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Mentions
1
Citations
24
Captures
112

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well